Literature DB >> 19539971

Early viral protein synthesis is necessary for NF-kappaB activation in modified vaccinia Ankara (MVA)-infected 293 T fibroblast cells.

Stefani Martin1, Joanna L Shisler.   

Abstract

Modified vaccinia Ankara (MVA) is an attenuated vaccinia virus, and is a promising vaccine vector for variola and monkeypox viruses, as well as for other pathogens. The MVA determinants important for vaccine efficacy and immunogenicity are poorly defined. MVA infection of fibroblast cells activates NF-kappaB, a characteristic not ascribed to wild-type vaccinia viruses. Thus, NF-kappaB activation, and the subsequent upregulation of host immune molecules, could be one of the determinants for MVA's immunogenicity. We report that ERK2 phosphorylation, an event preceding and required for NF-kappaB activation, occurred rapidly after virus infection. ERK2 and NF-kappaB remained inert when virus endocytosis was prevented, suggesting that virus-host cell interactions were insufficient for activating NF-kappaB. Inhibition of viral protein synthesis decreased NF-kappaB activation, and elimination of intermediate and late gene expression did not alter MVA-induced NF-kappaB activation. Thus, early gene expression activates NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19539971      PMCID: PMC2741392          DOI: 10.1016/j.virol.2009.05.014

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  29 in total

Review 1.  Transcriptional regulation via the NF-kappaB signaling module.

Authors:  A Hoffmann; G Natoli; G Ghosh
Journal:  Oncogene       Date:  2006-10-30       Impact factor: 9.867

Review 2.  Introduction to NF-kappaB: players, pathways, perspectives.

Authors:  T D Gilmore
Journal:  Oncogene       Date:  2006-10-30       Impact factor: 9.867

3.  The MC160 protein expressed by the dermatotropic poxvirus molluscum contagiosum virus prevents tumor necrosis factor alpha-induced NF-kappaB activation via inhibition of I kappa kinase complex formation.

Authors:  Daniel Brian Nichols; Joanna L Shisler
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  The identification and characterization of a monoclonal antibody to the vaccinia virus E3 protein.

Authors:  Jessica R Weaver; Mohammad Shamim; Edward Alexander; D Huw Davies; Philip L Felgner; Stuart N Isaacs
Journal:  Virus Res       Date:  2007-06-20       Impact factor: 3.303

5.  A novel cellular protein, VPEF, facilitates vaccinia virus penetration into HeLa cells through fluid phase endocytosis.

Authors:  Cheng-Yen Huang; Tsai-Yi Lu; Chi-Horng Bair; Yuan-Shau Chang; Jeng-Kuan Jwo; Wen Chang
Journal:  J Virol       Date:  2008-06-11       Impact factor: 5.103

6.  Double-stranded RNA-binding protein E3 controls translation of viral intermediate RNA, marking an essential step in the life cycle of modified vaccinia virus Ankara.

Authors:  Holger Ludwig; Yasemin Suezer; Zoe Waibler; Ulrich Kalinke; Barbara S Schnierle; Gerd Sutter
Journal:  J Gen Virol       Date:  2006-05       Impact factor: 3.891

7.  Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses.

Authors:  Zoe Waibler; Martina Anzaghe; Holger Ludwig; Shizuo Akira; Siegfried Weiss; Gerd Sutter; Ulrich Kalinke
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

8.  Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.

Authors:  Susana Guerra; José Luis Nájera; José Manuel González; Luis A López-Fernández; Nuria Climent; José M Gatell; Teresa Gallart; Mariano Esteban
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

9.  Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection.

Authors:  Christofer Samuelsson; Jürgen Hausmann; Henning Lauterbach; Michaela Schmidt; Shizuo Akira; Hermann Wagner; Paul Chaplin; Mark Suter; Meredith O'Keeffe; Hubertus Hochrein
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

Review 10.  Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses.

Authors:  J Hiscott; T-L A Nguyen; M Arguello; P Nakhaei; S Paz
Journal:  Oncogene       Date:  2006-10-30       Impact factor: 9.867

View more
  5 in total

1.  Viral double-stranded RNAs from vaccinia virus early or intermediate gene transcripts possess PKR activating function, resulting in NF-kappaB activation, when the K1 protein is absent or mutated.

Authors:  Kristen L Willis; Jeffrey O Langland; Joanna L Shisler
Journal:  J Biol Chem       Date:  2010-12-23       Impact factor: 5.157

2.  The C11R gene, which encodes the vaccinia virus growth factor, is partially responsible for MVA-induced NF-κB and ERK2 activation.

Authors:  Stefani Martin; Daniel T Harris; Joanna Shisler
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

Review 3.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

4.  The vaccinia virus O1 protein is required for sustained activation of extracellular signal-regulated kinase 1/2 and promotes viral virulence.

Authors:  Marc Schweneker; Susanne Lukassen; Michaela Späth; Michael Wolferstätter; Eveline Babel; Kay Brinkmann; Ursula Wielert; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

5.  Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes.

Authors:  Anna-Theresa Lülf; Astrid Freudenstein; Lisa Marr; Gerd Sutter; Asisa Volz
Journal:  Virology       Date:  2016-10-11       Impact factor: 3.616

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.